Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T05:14:12.390Z Has data issue: false hasContentIssue false
  • English
  • Français

A decade of biological psychiatric research on OCD (I): introduction and treatment-studies

Published online by Cambridge University Press:  18 September 2015

A.S. De Leeuw ,
J.A. Den Boer  and
H.G.M. Westenberg
A.S. De Leeuw*
Affiliation:
afd. biologische psychiatrie, AZU
J.A. Den Boer
Affiliation:
afd. biologische psychiatrie, AZU
H.G.M. Westenberg
Affiliation:
afd. biologische psychiatrie, AZU
*
Academisch Ziekenhuis Utrecht, Afdeling Biologische Psychiatrie, Heidelberglaan 100, 3584 CX Utrecht
Get access Rights & Permissions [Opens in a new window]

Summary

In this first part of a review on biological psychiatric aspects of obsessive-compulsive disorder (OCD), firstly a short introduction is given about historical, diagnostic and epidemiological issues concerning OCD. Subsequently pharmacologic treatment-studies are discussed. Only serotonin (5-HT) reuptake blockers are proven to be effective. There is accumulating evidence that this therapeutic effect is not due to antidepressant effects. The results of the treatment-studies strongly suggests that 5-HT is involved in OCD. CSF-studies seem to confirm this. Possibly the therapeutic effect is related with adaptive changes of 5-HT receptors. There is evidence that in a subgroup of O CD-patients the dopaminergic system is involved.

Keywords

obsessieve-compulsieve stoornisOCSserotonine5-hydroxyindolazijnzuurdopamineobsessieve-compulsieve stoornisOCSserotonine5-hydroxyindolazijnzuurdopamine
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 5 , Issue 1 , March 1993 , pp. 1 - 6
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Insel, TR. Phenomenology of obsessive-compulsive disorder. J clin Psychiat 1990; 51 (suppl. 2):4–8.Google ScholarPubMed
2.Karno, M, Goding, J, Sorenson, SB, Bumam, MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch gen Psychiat 1988; 45: 1094-9.CrossRefGoogle ScholarPubMed
3.Flament, MF, Whitaker, A, Rapoport, JL. Obsessive-compulsive disorder in adolescence: an epidemiologic study. J Am Acad Child Adol Psychiat 1988; 27: 764–771.CrossRefGoogle Scholar
4.Marks, IM, Stern, RS, Mawson, D, Cobb, J, McDonald, R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiat 1980;136: 1–25.CrossRefGoogle Scholar
5.Marks, IM, Lelliott, P, Basoglu, M, Noshirvani, H, Monteiro, W, Cohen, D, Kasvikis, Y. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiat 1988; 152: 522-34.CrossRefGoogle ScholarPubMed
6.Flament, MF, Rapoport, JL, Berg, CJ, Sceery, W, Kilts, C, Mellstrom, B, Linnoila, M. Clomipramine treatment of childhood obsessive-compulsive disorder. Arch gen Psychiat 1985; 42: 977-83.CrossRefGoogle ScholarPubMed
7.Leonard, HL, Swedo, SE, Rapoport, JL, Koby, EV, Lenane, MC, Cheslow, DL, Hamburger, SD. Treatment of obsessive-compulsive disorder with clomipramine an desipramine in children and adolescents: a double-blind crossover comparison. Arch gen Psychiat 1989; 46: 1088-92.CrossRefGoogle ScholarPubMed
8.Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch gen Psychiat 1991; 48: 730-8.CrossRefGoogle Scholar
9.DeVeaugh-Geiss, J, Phyllis Landau, MD, Katz, R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharm Bull 1989; 25: 36–40.Google ScholarPubMed
10.Thoren, P, Asberg, M, Cronholm, B, Jörnestedt, L, Träskman, LO. Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch gen Psychiat 1980; 37: 1281-5.CrossRefGoogle ScholarPubMed
11.Insel, TR, Mueller, EA, Alterman, I, Linnoila, M, Murphy, DL. Obsessive- compulsive disorder and serotonin: is there a connection? Biol Psychiat 1985; 20: 1174-88.CrossRefGoogle ScholarPubMed
12.Zohar, J, Insel, TR. Obsessive-compulsive disorder: psychobiolo-gical approaches to diagnosis, treatment, and patho-physiology. Biol Psychiat 1987; 22:667-87.CrossRefGoogle Scholar
13.Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch gen Psychiat 1989; 46: 36–44.CrossRefGoogle ScholarPubMed
14.Goodman, WK, Price, LH, Delgado, PL, Palumbo, J, Krystal, JH, Nagy, LM, Rasmussen, SA, Heninger, GR, Charney, DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch gen Psychiat 1990; 47: 577-85.CrossRefGoogle ScholarPubMed
15.Pigott, TA, Pato, MT, Bernstein, SE, Grover, GN, Hill, J, Tolliver, TJ, Murphy, DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch gen Psychiat 1990; 47: 926-32.CrossRefGoogle ScholarPubMed
16.Pato, MT, Pigott, TA, Hill, JL, Grover, GN, Bernstein, S, Murphy, DL. Controlled comparison of buspirone and clomipramine in obsessive- compulsive disorder. Am J Psychiat 1991; 148: 127-9.Google ScholarPubMed
17.McDougle, CJ, Price, L, Goodman, WK, Charney, DS, Heninger, GR. A controlled trial of lithium augmentation in fluvoxaminerefrac-tory obsessive- compulsive disorder: lack of efficacy. J clin Psy-chopharmacol 1991; 11: 175-84.Google ScholarPubMed
18.Stern, RS, Marks, IM, Mawson, D, Luscombe, DK. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br J Psychiat 1980; 136: 161-6.CrossRefGoogle ScholarPubMed
19.Kasvikis, Y, Marks, IM. Clomipramine in obsessive-compulsiveri-tualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects. Psychopharmacol 1988; 95:113-8.CrossRefGoogle ScholarPubMed
20.Mavissakalian, M, Jones, B, Olson, S, Perei, JM. The relationship of plasma clomipramine and n-desmethylclomipramine to response in obsessive- compulsive disorder. Psychopharmacol Bull 1990; 26:119-22.Google ScholarPubMed
21.Altemus, M, Pigott, T, Kalogeras, KT, Demitrack, M, Dubbert, B, Murphy, DL, Gold, PW. Abnormalities in the regulation of vasopressin and corticotropin releasing factor in obsessive-compulsive disorder. Arch gen Psychiat 1992; 49: 9–20.CrossRefGoogle ScholarPubMed
22.Leckman, JF, Goodman, WK, Riddle, MA, Hardin, MT, Anderson, GM. Low CSF 5- HIAA and obsessions of violence: report of two cases (letter). Psychiat Res 1990; 33: 95-9.CrossRefGoogle Scholar
23.Roy, A, Adinoff, B, Linnoila, M. Acting out hostility in normal volun- teers: negative correlation with levels of 5-HIAA in cerebrospinal fluid. Psychiat Res 1988; 24: 186-94.CrossRefGoogle Scholar
24.Weizman, A, Carmi, M, Hermesh, H, Shahar, A, Apter, A, Tyano, S, Rehavi, M. High-affinity Imipramine binding and serotonin uptake in platelets of eight adolescents and ten adult obsessive-compulsive patients. Am J Psychiat 1986; 143: 335-9.Google ScholarPubMed
25.Austin, SA, Lydiard, RB, Ballenger, JC, Cohen, BM, Laraia, MT, Zealberg, JJ, Fossey, MD, Elinwood, EH. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiat 1991; 30: 225-32.CrossRefGoogle ScholarPubMed